pocketful logo light
pocketful logo light
Jubilant Pharmova Ltd logo

Jubilant Pharmova Ltd

NSE: JUBLPHARMA BSE: 530019

₹970.90

(1.74%)

Sun, 05 Jul 2026, 00:06 am

mtf coin illustrationMTF 5x

Jubilant Pharmova Share Price Live Chart

1 Day

(1.74%)

No Result Found

Summary

  • Market Cap (in Cr)

    15828.05

  • Net Profit (in Cr)

    836.3

  • P/B

    2.25

  • Sector P/E

    33.76

  • P/E

    16.80

  • EV/EBITDA

    9.91

  • Debt/Equity (Industry)

    0.17

  • Interest Cover (Industry)

    18.17

  • ROCE (Industry)

    20.59

  • RONW (Industry)

    17.62

  • ROE

    9.50

  • ROCE

    8.39

  • Debt/Equity

    0.55

  • EPS (TTM)

    27.42

  • Dividend Yield

    0.50

  • Book Value

    445.26

  • Interest Cover

    3.58

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters47.6847.6847.6847.6850.68
FII15.9015.9616.5717.4017.22
DII11.6211.2210.529.537.05
Public24.8025.1425.2325.3925.06
Government00000

Read More

Technical Analysis

RSI

49.31

MACD

-0.64

50 DMA

974.24

200 DMA

1001.21

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1102.851037.201004.05971.55938.40905.90840.25
Fibonacci1037.201012.12996.63971.55946.47930.98905.90
Camarilla988.95982.94976.92971.55964.88958.86952.85

Pivots Level: Classic

R3

+131.30

1102.85

R2

+65.65

1037.20

R1

+32.50

1004.05

971.55
971.55
Pivot Point
LTP: 969.20

S1

-33.15

938.40

S2

-65.65

905.90

S3

-131.30

840.25

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    970.22

  • 20-EMA

    971.62

  • 30-EMA

    970.27

  • 50-EMA

    963.59

  • 100-EMA

    962.14

  • 200-EMA

    980.20

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
22 May 2026board-meetingsAccounts, Final Dividend
06 Feb 2026board-meetingsQuarterly Results
31 Oct 2025board-meetingsQuarterly Results
06 Aug 2025agm
25 Jun 2025dividendFinal Dividend - Rs. - 525 Jul 2025
16 May 2025dividend₹5.00 Dividend /Share25 Jul 2025
09 Aug 2024agm
02 Jul 2024dividendFinal Dividend - Rs. - 502 Aug 2024
29 May 2024dividend₹5.00 Dividend /Share02 Aug 2024
07 Aug 2023agm

Read More

Peer Comparison

Jubilant Pharmova Ltd logo

Jubilant Pharmova Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Read More

Jubilant Pharmova Ltd About

Jubilant Pharmova in radiopharma, allergy immunotherapy, contract development and manufacturing of sterile injectable, generics, contract research development and manufacturing and proprietary novel drugs businesses.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1978

Headquarters

CEO

Shyam S Bhartia

Employees

Contact

Website icon

Website

http://www.jubl.com

Email icon

Email

investors@jubl.com

Phone icon

Phone

91-5924-267200

Location icon

Location

Bhartiagram Gajraula, , Amroha, Uttar Pradesh, 244223

Read More

Jubilant Pharmova Ltd Company History

YearHistory
2019
  • Celebrated decade of Social Entrepreneur of the Year India Awards partnership.
2020
  • Supported COVID-19 efforts with health/safety materials in Karnataka and free hand sanitizers.
  • Launched JUBI-R (remdesivir) in India for COVID-19 treatment.
  • Hindustan Times Fellowship Seed Transformation Program with Schwab Foundation.
2021
  • Company name changed to Jubilant Pharmova Ltd.
  • Undertaking of Jubilant Generics Limited.
2022
  • Jubilant HollisterStier announced CAD 100 Mn expansion of CMO facility in Montreal, Canada.
  • Jubilant HollisterStier entered $149.6 Mn cooperative agreement with US Government for vaccine manufacturing capacity expansion.
  • Presented data on Isoform Selective PAD4 inhibitors at AACR Meeting.
  • Received FDA clearance of IND for JBI-802, a dual LSD1 and HDAC6 inhibitor for solid tumors.
2023
  • Received additional funding from Government of Canada for Montreal facility expansion.
  • Radiopharma business received USFDA approval for Technetium Tc-99m Mertiatide injection.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
JUBILANT ENPRO PRIVATE LIMITEDbulkSell2116000106013 Jun 2025
KOTAK MAHINDRA MUTUAL FUNDbulkBuy1693434106013 Jun 2025
KOTAK FUNDS - INDIA MIDCAP FUNDbulkBuy1593500106013 Jun 2025
NIKITA RESOURCES PRIVATE LIMITEDbulkSell19624341060.3713 Jun 2025
EAST BRIDGE CAPITAL MASTER FUND I LTDblockBuy623585856.2518 Mar 2025
EAST BRIDGE CAPITAL MASTER FUND LIMITEDblockSell623585856.2518 Mar 2025
GRAVITON RESEARCH CAPITAL LLPbulkBuy8252891157.7213 Sept 2024
GRAVITON RESEARCH CAPITAL LLPbulkSell8252891158.1813 Sept 2024
EAST BRIDGE CAPITAL MASTER FUND I LTDblockBuy140500085105 Aug 2024
EAST BRIDGE CAPITAL MASTER FUND LIMITEDblockSell140500085105 Aug 2024

Read More

Jubilant Pharmova Ltd News

Jubilant Pharmova subsidiary gets tax order

Jubilant Pharmova Ltd's subsidiary received a tax rectification order for AY 2019-20 disallowing Rs 53.37 Cr losses. The company plans to appeal.

30 Jun 2026

companies

Jubilant Pharmova unit gets USFDA nod

Jubilant Pharmova's subsidiary received tentative USFDA approval for Pantoprazole Sodium Delayed Release Oral Suspension. Final approval is expected in December 2026.

25 Jun 2026

companies

Jubilant Pharmova unit gets tax relief

Jubilant Generics Limited received a rectification order reducing tax adjustments for AY 2023-24 from Rs. 107.89 crs to Rs. 42.41 crs, restoring tax losses of Rs. 65.48 crs.

24 Jun 2026

companies

USFDA inspection concludes at Spokane facility

Jubilant Pharmova announced the USFDA concluded its inspection at the Spokane facility on June 17, 2026, issuing eight observations unrelated to sterility.

18 Jun 2026

companies

Jubilant Pharmova unit gets tax order

Jubilant Generics received an Income Tax order for FY23 with adjustments of ₹107.89 crore. The subsidiary plans to appeal the order.

22 May 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number